OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - NOVO-NORDISK B | Delayed Deutsche Boerse AG 02:49:05 2024-06-14 am EDT | ||
| 21.78 EUR | -0.18% |
|
| Current month | +8.07% | ||
| 1 month | +9.54% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 21.78 | -0.18% |
| 24-06-13 | 21.82 | -0.50% |
| 24-06-12 | 21.93 | +0.97% |
| 24-06-11 | 21.72 | -1.76% |
| 24-06-10 | 22.11 | +1.01% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 02:49 am EDT
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | CU988F |
| ISIN | DE000CU988F8 |
| Date issued | 2019-08-12 |
| Strike | 170.3 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.44 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.11 € |
|---|---|
| Lowest since issue | 0.37 € |
| Spread | 0.01 € |
| Spread % | 0.05% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
979.7
DKK
Average target price
929.5
DKK
Spread / Average Target
-5.13%
- Stock Market
- Certificates
- Certificat
